Becton Dickinson (BDX) is portrayed through numerous stories, from partnerships to lawsuits, financial transitions to competitive positioning. The company's new immunology partnership with the
University of Pennsylvania reveals strategic growth and collaborative efforts. However, a lawsuit over alleged
hernia mesh monopoly suggests some controversy in the company's business practices. Financial movements within the organization are indicated by transitions in Chief Financial Officer roles and divestment from various stakeholders including
Trust Co. of Vermont and
Ossiam. The
RBC Capital's consistent sector performance recommendation highlights perceived stability. Speculations on the recent share price decline ask if this presents a long-term investment opportunity. Coverages on the declaration and increase of the company's dividends for the
54th consecutive year denote the company’s consistent performance. Regarding product innovation, BD’s work around everyday
hospital safety workflows is considered progressive and potentially beneficial to long-term market value. Nonetheless, shareholders remain in red over the years, yet the company’s CEO compensation for 2025 was revealed, and analysts brace for
BD's Q4 and Full Fiscal Year 2025 results.
Becton Dickinson and BDX News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Fri, 26 Dec 2025 10:08:04 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -4
